

KENYA

Support for Pneumococcal Conjugate Vaccine (PCV)

This Decision Letter sets out the Programme Terms of a Programme

1. Country:	Kenya						
2. Vaccine grant number:	08-KEN-08b-Y, 09-KEN-08c-Y, 1115-KEN-12B-X, 16-KEN-12b-X, 17-KEN-12b-X, 18-KEN-25a-Y, 1819-KEN-12a-X, 20-KEN-12a-X						
3. Date of Decision Letter:	30-Sep-2019						
4. Date of the Partnership Framework Agreement:	25 November 2014						
5. Programme title:	New Vaccine Support (NVS), PCV, Routine						
6. Vaccine type:	Pneumococcal Conjugate Vaccine						
7. Requested product presentation and formulation of vaccine:	PCV10, 4 doses per vial, LIQUID						
8. Programme Duration:¹	2009-2020						
9. Programme Budget (indicative):²	(subject to the terms of the Partnership Framework Agreement, if applicable)						
	2009-2019	2020	2021	2022	2023	2024	Total²
Programme Budget (US\$)	197,834,472	11,189,500	-	-	-	-	209,023,972
10. Vaccine introduction grant							
	Approval						
	Year	Grant Number					Amount (US\$)
	2008	08-KEN-08b-Y					443,500
	Disbursement						
	Disbursement date						Amount (US\$)
	04 August, 2010						443,500
11. Product switch grant							
	Approval						
	Year	Grant Number					Amount (US\$)
	2018	18-KEN-25a-Y					379,460
	Disbursement						
	Disbursement date						Amount (US\$)
	25 February, 2019						370,531
12. Indicative Annual Amounts:³	(subject to the terms of the Partnership Framework Agreement, if applicable)						

¹ This is the entire duration of the programme.

² This is the total amount endorsed by Gavi for the entire duration of the programme.

³ This is the amount that Gavi has approved.

Type of supplies to be purchased with Gavi funds	2010-2019	2020	2021
Number of vaccine doses		3,349,100	-
Annual Amounts (US\$)	197,834,472	11,189,500	-

13. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.

14. Self-procurement: Not applicable

15. Co-financing obligations:

According to the co-financing policy, the Country falls within the group: Preparatory transition phase

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2020	2021	2022	2023	2024
Number of vaccine doses	519,600	-	-	-	-
Number of AD syringes	514,700	-	-	-	-
Number of re-constitution syringes	-	-	-	-	-
Number of safety boxes	5,675	-	-	-	-
Value of vaccine doses (US\$)	1,583,941	-	-	-	-
Total co-financing payments (US\$) (including freight)	1,620,500	-	-	-	-

16. Operational support for campaigns:
Not applicable

17. Additional Reporting Requirements:

	Due dates
<p>To prepare for the annual procurement of vaccines, Country shall submit the following information each year:</p> <ul style="list-style-type: none"> Vaccine stock levels including buffer stock Number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received Country shall report the actual switch date in the first renewal request following the actual implementation. 	<p>Quarterly</p> <p>15 May 2020</p>

In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.

To be agreed with Gavi Secretariat

18. Financial clarifications: Not applicable

Signed by,
On behalf of Gavi



Thabani Maphosa,
Managing Director, Country Programmes
30-Sep-19